Speculative biotech shorts weighed on this hedge fund’s results – ValueWalk Premium
Stock Market

Speculative biotech shorts weighed on this hedge fund’s results

Sio Partners was down 4.8% net for September, compared to the S&P 500 Total Return Index's decline of 3.8%, the MSCI World Healthcare Index's 1.5% decline, and the MSCI World Index's 3.6% decline. Sio's long positions detracted 2.4% during September, while its shorts detracted 2.3%.

Q3 2020 hedge fund letters, conferences and more

A difficult September
In his September letter to investors, which . . .

SORRY!

This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email support@valuewalk.com or click Chat.


X
Saved Articles
X
TextTExtLInkTextTExtLInk
Here’s a Tip: Read What Professional Investors Read

ValueWalk Premium is for investors looking to improve their investment process AND keep up-to-date on the latest industry trends.

It’s THE resource for value investing and hedge funds.   

And with a free three-day trial and $29.99 per month thereafter, it’s a value in its own right.

SIGN UP NOW
0